The stock of Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) reached all time low today, Oct, 12 and still has $5.14 target or 11.00% below today’s $5.77 share price. This indicates more downside for the $402.90 million company. This technical setup was reported by Barchart.com. If the $5.14 PT is reached, the company will be worth $44.32 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 184,265 shares traded hands or 13.77% up from the average. Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) has declined 21.34% since March 9, 2016 and is downtrending. It has underperformed by 28.76% the S&P500.
Analysts await Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) to report earnings on November, 11. They expect $-0.23 earnings per share, down 1,050.00% or $0.21 from last year’s $-0.02 per share. After $-0.31 actual earnings per share reported by Adaptimmune Therapeutics PLC – ADR for the previous quarter, Wall Street now forecasts -25.81% EPS growth.
According to Zacks Investment Research, “Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom.”
More notable recent Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) news were published by: Marketwatch.com which released: “Adaptimmune Therapeutics PLC ADR” on April 14, 2015, also Quotes.Wsj.com with their article: “DOW JONES, A NEWS CORP COMPANY” published on November 29, 2014, Equitiesfocus.com published: “Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) Basic Net EPS Stands At $-0.3783” on September 17, 2016. More interesting news about Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) were released by: Equitiesfocus.com and their article: “Quarterly EPS Estimate For Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) Is …” published on September 23, 2016 as well as Equitiesfocus.com‘s news article titled: “Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) Quarterly EPS Estimate At $-0.28” with publication date: September 30, 2016.
ADAP Company Profile
Adaptimmune Therapeutics plc, incorporated on December 03, 2014, is a clinical-stage biopharmaceutical company. The Firm is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Firm has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Firm develops TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.